Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sangamo Biosciences (NASDAQ: SGMO) and VBI Vaccines (NASDAQ: VBIV)

By Jason Carr

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sangamo Biosciences (NASDAQ: SGMO) and VBI Vaccines (NASDAQ: VBIV).

Sangamo Biosciences (NASDAQ: SGMO)

Wedbush analyst Liana Moussatos reiterated a Hold rating on Sangamo Biosciences (NASDAQ: SGMO) today and set a price target of $8. The company’s shares opened today at $26.10, close to its 52-week high of $27.50.

According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 9.7% and a 41.9% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Catabasis Pharmaceuticals.

Sangamo Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $28.40.

VBI Vaccines (NASDAQ: VBIV)

Canaccord Genuity analyst John Newman maintained a Buy rating on VBI Vaccines (NASDAQ: VBIV) today and set a price target of $10. The company’s shares opened today at $4.06.

Newman commented:

“We traveled with VBI management last week in Boston and noted good reception and enthusiasm around the lead program Sci-B-Vac for Hepatitis B. Enrollment is proceeding well in Phase 3, which we anticipate could be complete during 2Q18. VBI still expects top-line Phase 3 data in mid-2019, which we expect to easily show non- inferiority to GSK’s Engerix-B, and which could show superiority in adults age 45 or older. Interestingly, VBI will also measure seroprotection after 2 doses of Sc-B-Vac vs 3 doses of Engerix-B, which we expect to be positive for Engerix-B as well. In our view, over the long-term, Sci-B-Vac could show a profile suggesting 2 dose protection in patients of all ages, greatly expanding the market opportunity, which we conservatively project to be $370M WW.”

According to TipRanks.com, Newman is a 5-star analyst with an average return of 17.5% and a 45.2% success rate. Newman covers the Healthcare sector, focusing on stocks such as Hutchison China MediTech Ltd, Synergy Pharmaceuticals Inc, and Rocket Pharmaceuticals Inc.

VBI Vaccines has an analyst consensus of Moderate Buy, with a price target consensus of $10.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.